Recoly N.V. – Product Pipeline Review – Q4 2010

Date: November 1, 2010
Pages: 24
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: RB465333720EN
Leaflet:

Download PDF Leaflet

Recoly N.V. – Product Pipeline Review – Q4 2010
Recoly N.V. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Recoly N.V. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Recoly N.V. – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Recoly N.V. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Recoly N.V. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Recoly N.V.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Recoly N.V.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Recoly N.V. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Recoly N.V.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Recoly N.V..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Recoly N.V. and identify potential opportunities in those areas.
Recoly N.V. Snapshot
Recoly N.V. Overview
Key Information
Key Facts
Recoly N.V. – Research and Development Overview
Key Therapeutic Areas
Recoly N.V. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Recoly N.V. – Pipeline Products Glance
Recoly N.V. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Recoly N.V.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Recoly N.V. – Drug Profiles
LongSeven
  Product Description
  Mechanism of Action
  R&D Progress
NecLip-G-CSF
  Product Description
  Mechanism of Action
  R&D Progress
REC-200-Liposomal Glucocorticoid
  Product Description
  Mechanism of Action
  R&D Progress
Recoly N.V. – Pipeline Analysis
Recoly N.V. – Pipeline Products by Therapeutic Class
Recoly N.V. Pipeline Products By Target
Recoly N.V. – Pipeline Products by Route of Administration
Recoly N.V. – Pipeline Products by Molecule Type
Recoly N.V. – Locations And Subsidiaries
Head Office
Recent Developments
Jul 20, 2009: Recoly Completes A Phase I/II Clinical Trial With LongSeven
Dec 15, 2008: Recoly Initiates A Phase I/II Clinical Trial With LongSeven
Financial Deals Landscape
Recoly N.V., Deals Summary, 2004 to 2010
Recoly N.V. Detailed Deal Summary
Licensing Agreements
Recoly Enters Into Licensing Agreement With Innovative Drug Delivery
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Recoly N.V. – Pipeline by Therapy Area and Indication, 2010
Recoly N.V. – Pipeline by Stage of Development, 2010
Recoly N.V. – Monotherapy Products in Pipeline, 2010
Recoly N.V. - Phase II, 2010
Recoly N.V. - Pipeline By Therapeutic Class, 2010
Recoly N.V. - Pipeline By Target, 2010
Recoly N.V. – Pipeline By Route of Administration, 2010
Recoly N.V. – Pipeline By Molecule Type, 2010
Recoly N.V., Deals Summary, 2004 to 2010 21

LIST OF FIGURES

Recoly N.V. – Pipeline by Therapy Area and Indication, 2010
Recoly N.V. – Pipeline by Stage of Development, 2010
Recoly N.V. – Monotherapy Products in Pipeline, 2010
Recoly N.V. – Pipeline By Therapeutic Class, 2010
Recoly N.V. - Pipeline By Target, 2010
Recoly N.V. – Pipeline By Route of Administration, 2010
Recoly N.V. – Pipeline By Molecule Type, 2010 18
Recoly N.V. – Product Pipeline Review – Q1 2011 US$ 500.00 Apr, 2011 · 28 pages
Recoly N.V. – Product Pipeline Review – H2 2011 US$ 500.00 Oct, 2011 · 25 pages
Bial Group - Product Pipeline Review - Q4 2010 US$ 500.00 Nov, 2010 · 28 pages
Celentyx - Product Pipeline Review - Q4 2010 US$ 500.00 Nov, 2010 · 40 pages

Ask Your Question

Recoly N.V. – Product Pipeline Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: